Tagged as: Henlius

Organon and Henlius license agreement - Big Molecule Watch

Organon announced yesterday that it has entered into an agreement with Henlius, whereby Organon will license commercialization rights for biosimilar candidates referencing PERJETA® (pertuzumab) and PROLIA®/XGEVA® (denosumab).  According to the press release, Henlius independently developed both biosimilar products.  Organon will acquire exclusive global commercialization rights except for China.  The agreement…

Read More